BiotechTube

PF-06730512

Phase 2Terminated
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis (FSGS)

Conditions

Focal Segmental Glomerulosclerosis (FSGS)

Trial Timeline

Oct 15, 2018 → Feb 14, 2023

NCT ID
NCT03448692

About PF-06730512

PF-06730512 is a phase 2 stage product being developed by Pfizer for Focal Segmental Glomerulosclerosis (FSGS). The current trial status is terminated. This product is registered under clinical trial identifier NCT03448692. Target conditions include Focal Segmental Glomerulosclerosis (FSGS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03448692Phase 2Terminated

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis (FSGS)

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
85
DapagliflozinAstraZenecaApproved
85
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
52
CCX140-BAmgenPhase 2
51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
84
VX-147Vertex PharmaceuticalsPhase 2
51
VX-147Vertex PharmaceuticalsPhase 1
32
IXPVertex PharmaceuticalsPhase 1
32
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
51
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
32
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
51
VivaglobinCSLPhase 2
51
UCB0942UCBPhase 2
49
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
82
Brivaracetam + BrivaracetamUCBPhase 2
49
LacosamideUCBPhase 2
49
UCB0942 + UCB0942 + PlaceboUCBPhase 2
49
LacosamideUCBPre-clinical
20
ARGX-117ArgenxPhase 2
49
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
74

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84